Nadroparin calcium: Difference between revisions

{{Short description|Chemical compound}}

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 450486588

| IUPAC_name = (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate

| image = File:Heparin General Structure V.1.svg

<!-- Clinical data -->

| tradename = Fraxiparin(e), Fraxodi, others

| legal_AU = S4

| legal_CA = Rx-only

| legal_UK =

| routes_of_administration = [[Subcutaneous injection]] (except for [[haemodialysis]])

<!-- Pharmacokinetic data -->

| bioavailability = 89% (SC dose)

| elimination_half-life = 3.7 hours (SC dose)

| excretion = clearance 21.4mL/min (+/- 7)

<!-- Identifiers -->

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 9005-49-6

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 1K5KDI46KZ

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB08813

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D07510

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = <!-- Chemical data -->

| chemical_formula =

| molecular_weight = 4300

| molecular_weight_comment = g/mol

}}

'''Nadroparin''' (trade names '''Fraxiparin[e]''', '''Fraxodi''', among others) is an anticoagulant belonging to a class of drugs called [[low molecular weight heparin]]s (LMWHs). Nadroparin was developed by [[Sanofi#Sanofi-Synthélabo|Sanofi-Synthélabo]].

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders ([[deep vein thrombosis]] and [[pulmonary embolism]]), and as treatment for [[deep vein thrombosis]]. It is also used to prevent clotting during [[hemodialysis]], and for treatment of [[unstable angina]] and non-Q wave [[myocardial infarction]].<ref name= "Aspri Canada">{{cite web|title=Fraxiparine PRODUCT MONOGRAPH (Canada)|url=http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf|website=Aspripharma.com|access-date=2 April 2019}}</ref>

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref>

==References==

{{Reflist}}

* {{cite web|url=https://www.cancer.gov/publications/dictionaries/cancer-drug|title=NCI Drug Dictionary|date=2 February 2011|website=National Cancer Institute|access-date=2 April 2019}}

* {{cite journal |vauthors=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136–43 |year=2006 |pmid=17057417 |doi=10.1159/000096484|s2cid=95878036 }}

[[Category:Heparins]]